Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $1.45 billion. The enterprise value is $1.56 billion.
Important Dates
The last earnings date was Tuesday, March 17, 2026, after market close.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 48.40 million shares outstanding. The number of shares has increased by 10.33% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.40M |
| Shares Change (YoY) | +10.33% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 3.29% |
| Owned by Institutions (%) | 7.40% |
| Float | 31.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 128.22 |
| Forward PS | 8.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 130.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63
| Current Ratio | 0.63 |
| Quick Ratio | 0.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -41.64% |
| Return on Invested Capital (ROIC) | -567.28% |
| Return on Capital Employed (ROCE) | 245.90% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | $115,832 |
| Profits Per Employee | -$588,830 |
| Employee Count | 103 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -43,453 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +696.10% in the last 52 weeks. The beta is 0.57, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +696.10% |
| 50-Day Moving Average | 26.05 |
| 200-Day Moving Average | 16.97 |
| Relative Strength Index (RSI) | 52.72 |
| Average Volume (20 Days) | 59,465 |
Short Selling Information
The latest short interest is 15,389, so 0.03% of the outstanding shares have been sold short.
| Short Interest | 15,389 |
| Short Previous Month | 63,474 |
| Short % of Shares Out | 0.03% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $11.93 million and -$60.65 million in losses. Loss per share was -$1.28.
| Revenue | 11.93M |
| Gross Profit | 11.93M |
| Operating Income | -51.59M |
| Pretax Income | -60.69M |
| Net Income | -60.65M |
| EBITDA | -51.49M |
| EBIT | -51.59M |
| Loss Per Share | -$1.28 |
Full Income StatementBalance Sheet
The company has $33.84 million in cash and $60.18 million in debt, with a net cash position of -$26.33 million or -$0.54 per share.
| Cash & Cash Equivalents | 33.84M |
| Total Debt | 60.18M |
| Net Cash | -26.33M |
| Net Cash Per Share | -$0.54 |
| Equity (Book Value) | -80.98M |
| Book Value Per Share | -1.68 |
| Working Capital | -27.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.55 million and capital expenditures -$595,420, giving a free cash flow of -$36.62 million.
| Operating Cash Flow | -36.55M |
| Capital Expenditures | -595,420 |
| Depreciation & Amortization | 94,928 |
| Net Borrowing | -5.33M |
| Free Cash Flow | -36.62M |
| FCF Per Share | -$0.76 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -432.39% |
| Pretax Margin | -508.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.33% |
| Shareholder Yield | -10.33% |
| Earnings Yield | -3.96% |
| FCF Yield | -2.39% |
Analyst Forecast
The average price target for Nanobiotix is $26.00, which is -13.07% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.00 |
| Price Target Difference | -13.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -2.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.82 |
| Piotroski F-Score | 1 |
